Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ASND
vs
S&P 500
ASND
S&P 500
Over the past 12 months, ASND has outperformed S&P 500, delivering a return of +25% compared to S&P 500's +11% growth.
Stocks Performance
ASND vs S&P 500
Performance Gap
ASND vs S&P 500
Performance By Year
ASND vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ascendis Pharma A/S
Glance View
Ascendis Pharma is a biopharmaceutical company that develops and sells medicines for rare endocrine diseases. Its main products are long-acting treatments built with its TransCon technology, which is designed to release medicine slowly so patients do not need frequent dosing. The company sells these drugs to specialty pharmacies, hospitals, doctors, and the payers that cover treatment for patients with chronic hormone disorders. The company makes money mainly from selling approved medicines and, in some cases, from partnerships around its drug technology. Its best-known products treat conditions such as growth hormone deficiency in children and hypoparathyroidism in adults. That means Ascendis is not a broad drugmaker; it focuses on a small set of hard-to-treat diseases where easier dosing can matter a lot to patients and doctors. What sets Ascendis apart is that it tries to turn short-lived hormone or protein medicines into longer-acting versions. This can improve convenience and may help patients stay on therapy, which is especially important in rare diseases that need lifelong treatment. In simple terms, Ascendis sits between drug discovery and specialty care, using its own drug-delivery platform to create and commercialize niche medicines.
